There are certain stocks that attract attention because everyone is already talking about them, and then there are stocks that become interesting precisely because almost nobody seems to care.
H.B. Fuller falls into the second category for me.
This is not a flashy artificial intelligence company. It is not a consumer brand dominating social media. It is not the latest market darling trading at a valuation that requires investors to believe earnings will double every other Tuesday.
H.B. Fuller makes adhesives.
That sounds boring until you realize how many industries depend on adhesives, sealants, coatings, and specialty chemical solutions to manufacture everyday products. Packaging, construction, hygiene products, electronics, transportation, medical applications, woodworking, and countless industrial processes all require materials that hold things together, bond surfaces, seal components, and perform reliably under specific conditions.
In other words, H.B. Fuller operates in one of those wonderfully unglamorous corners of the economy where the products are essential even if investors rarely talk about them.
And that is exactly why the stock caught my attention.
The shares recently closed at $50.23, giving the company a market capitalization of roughly $2.7 billion. The stock is down around 14% over the past year and trades at approximately 9.7 times forward earnings.
Normally, a stock trading at that kind of valuation would make me wonder what is going wrong.
What is the market seeing?
Are margins deteriorating?
Is revenue shrinking?
Is management losing control of costs?
Is debt getting worse?
Is the company facing a structural decline?
Those are the questions I would immediately ask.
But in H.B. Fuller's case, the latest numbers tell a very different story.
Revenue increased 5.2%.
Organic revenue grew 4.4%.
Adjusted EBITDA increased 9%.
Adjusted earnings per share climbed 21%.
Adjusted gross margin improved by 120 basis points.
Adjusted EBITDA margin reached a record 19.9%.
That is where the story becomes interesting to me.
The stock has been falling while profitability has been improving.
The valuation has been contracting while margins have been expanding.
The market is becoming more skeptical at the same time the company is becoming more efficient.
That kind of contradiction is exactly what I look for.
Why I Pay Attention When Price and Fundamentals Move in Opposite Directions
One of the biggest mistakes investors make is assuming stock prices and business performance always move together in real time.
They do not.
Sometimes the stock market rewards a company long before the business actually improves.
Other times the business improves while the stock continues drifting lower because investors remain focused on yesterday's problems.
Those disconnects can create opportunity.
That does not mean every declining stock is cheap.
Plenty of stocks are falling because the underlying business is deteriorating.
A low valuation alone tells me almost nothing.
What interests me is the combination of valuation and improving fundamentals.
That is the difference between something being inexpensive and something potentially being undervalued.
H.B. Fuller currently checks several boxes that I like.
The valuation is relatively modest.
Earnings are growing.
Margins are expanding.
Cash flow remains meaningful.
Leverage is improving.
And an insider recently purchased shares in the open market.
None of those things individually guarantee anything.
Taken together, however, they create a setup that deserves attention.
I am not buying a stock simply because a director bought shares.
I am not buying a stock simply because it trades below 10 times forward earnings.
And I am certainly not buying a stock simply because its price has fallen.
What interests me is the pattern.
The market is pricing H.B. Fuller as if something is structurally wrong while the company's operating performance appears to be moving in the opposite direction.
That contradiction deserves investigation.
The Margin Story May Be the Most Important Part
If there is one number in the recent report that stands out to me, it is the 19.9% adjusted EBITDA margin.
That is a record.
And it matters because margin expansion tells us more than revenue growth alone.
A company can grow revenue in ways that do not necessarily improve shareholder value.
It can acquire other companies.
It can cut prices.
It can chase low-quality sales.
It can grow revenue while profitability barely moves.
Margin expansion tells a more useful story.
It tells us that each dollar of revenue is becoming more productive.
H.B. Fuller increased adjusted gross margin by 120 basis points while adjusted EBITDA grew 9%.
Adjusted EPS rose even faster at 21%.
That is operating leverage.
When earnings grow materially faster than revenue, it usually means the company is doing a better job converting sales into profit.
That can happen through pricing discipline, cost management, restructuring, procurement improvements, portfolio optimization, better product mix, or some combination of those factors.
Whatever the exact combination is, the result matters.
H.B. Fuller is generating better economics from the business.
And if the company can push adjusted EBITDA margin beyond 20%, I think the market may begin reconsidering what multiple the stock deserves.
The difference between a company permanently stuck in the mid-teens on margins and one consistently producing margins around 20% can be enormous from a valuation perspective.
A higher-quality earnings stream deserves a higher valuation.
That is why I view the company's margin progression as potentially more important than the headline revenue growth rate.
Revenue Growth Is Solid, but I Am Watching the Composition
Revenue growth of 5.2% sounds perfectly respectable.
Organic revenue growth of 4.4% is also encouraging.
But I do not want to stop there.
I want to understand how that growth is being created.
One of the concerns with H.B. Fuller is that organic volume remains soft.
That matters.
If a company is growing primarily because it is raising prices while unit demand remains weak, there is a limit to how long that strategy can carry results.
Pricing power is valuable, but I would eventually like to see volume participate.
The strongest earnings stories usually involve both.
Higher pricing.
Better mix.
Stable or growing volumes.
Expanding margins.
That is the ideal combination.
H.B. Fuller is not fully there yet.
The company has demonstrated that it can protect profitability even in a softer demand environment, and that deserves credit.
But at some point, I want to see improving volumes validate the idea that the business is not simply extracting more dollars from stagnant demand.
If industrial activity strengthens, construction improves, electronics demand continues recovering, or broader manufacturing conditions become more favorable, H.B. Fuller could get a meaningful tailwind.
That would make the margin story even more powerful.
Right now, the company is showing it can improve profitability without strong volume growth.
Imagine what the numbers could look like if volume actually returned.
That is part of the upside case.
Cash Flow Gives the Story Some Substance
Management expects adjusted EBITDA of roughly $655 million to $670 million for the year.
Operating cash flow, excluding AMS-related items, is expected to land between $300 million and $325 million.
Those are important numbers because accounting earnings can look impressive while cash flow tells a very different story.
I care about cash.
Cash pays down debt.
Cash funds dividends.
Cash supports acquisitions.
Cash can be used for share repurchases.
Cash strengthens the balance sheet.
Cash gives management flexibility.
A company generating hundreds of millions of dollars in operating cash flow has options.
And H.B. Fuller needs those options because the balance sheet remains one of the biggest reasons I would stay disciplined with this stock.
The company still carries nearly $2 billion in net debt.
That is not insignificant.
It is the main reason I would resist becoming overly enthusiastic based solely on the valuation.
Cheap stocks often remain cheap because there is something investors do not completely trust.
In this case, leverage and acquisition execution are obvious candidates.
Debt Is the Main Thing Keeping Me From Calling This Easy
Net debt to adjusted EBITDA has improved from 3.3 times a year ago to roughly 3.0 times.
That is progress.
But three times leverage is still meaningful.
It is not disastrous.
It is not necessarily dangerous.
But it is high enough that I would continue monitoring it closely.
If the company were debt-free or sitting on a large net cash position, I suspect the stock would command a higher valuation.
Debt creates uncertainty.
It reduces flexibility.
It increases sensitivity to interest rates.
It makes acquisitions riskier.
It places more pressure on management to execute consistently.
It also changes the way investors value earnings.
Two companies can produce identical EBITDA, but the company carrying heavy debt deserves a lower equity valuation than the company carrying none.
That is simply financial reality.
So when I see H.B. Fuller trading below 10 times forward earnings, I do not immediately assume the market is irrational.
Part of that discount is justified.
The question is whether the discount has become too large relative to the company's improving fundamentals.
That is the opportunity.
If H.B. Fuller keeps expanding margins while reducing leverage, the market loses one of its strongest arguments for keeping the valuation depressed.
That could create meaningful multiple expansion.
And multiple expansion layered on top of earnings growth is where things get interesting.
Deleveraging Could Become a Catalyst
I often think investors underestimate how powerful balance-sheet improvement can be.
The market tends to focus on revenue growth and earnings growth because they are easy to understand.
Debt reduction is less exciting.
Nobody turns on financial television to hear someone passionately discuss net leverage moving from 3.0 times to 2.5 times.
But for shareholders, that kind of improvement can matter tremendously.
Lower leverage reduces risk.
Lower leverage lowers interest expense over time.
Lower leverage increases strategic flexibility.
Lower leverage makes future acquisitions less concerning.
Most importantly, lower leverage can change investor perception.
If H.B. Fuller can demonstrate a clear path toward reducing net debt while maintaining margins near 20%, I think the stock's valuation could begin looking increasingly difficult to justify at current levels.
The market may eventually shift from viewing H.B. Fuller as a leveraged industrial chemicals company to viewing it as a higher-quality specialty materials company with improving margins and a healthier balance sheet.
That perception change could matter almost as much as the earnings growth itself.
The AMS Integration Is Another Piece I Am Watching
Acquisitions are always complicated.
Management presentations make them look clean.
Synergy targets are presented in neat charts.
Integration timelines look orderly.
Everything appears manageable.
Reality is usually messier.
Employees leave.
Systems do not integrate perfectly.
Customer relationships take time to consolidate.
Cost savings arrive later than expected.
Different corporate cultures collide.
Manufacturing networks must be optimized.
And management teams can spend years explaining why the benefits are still "ahead of schedule" even while the schedule keeps moving.
That is why acquisition-heavy strategies make me cautious.
H.B. Fuller's AMS acquisition adds opportunity, but it also adds execution risk.
If management integrates the business successfully, captures expected synergies, strengthens margins, and generates enough cash to reduce leverage, the acquisition could become a major driver of long-term value.
If integration proves more difficult, the opposite could happen.
That is why AMS execution belongs near the top of my list of things to monitor.
The current earnings momentum suggests management is making progress.
But I would not declare victory yet.
The next several quarters matter.
Insider Buying Gets My Attention, but I Do Not Overrate It
Director Michael Happe recently purchased 2,000 shares at approximately $49.625, investing around $99,000.
I like seeing that.
Open-market insider buying carries a different signal than insider selling.
Executives and directors sell shares for countless reasons.
Taxes.
Diversification.
Estate planning.
Major purchases.
Liquidity needs.
A sale does not automatically mean anything is wrong.
Buying is different.
There are fewer reasons for insiders to reach into their own pockets and purchase shares.
Normally, they do it because they believe the stock is worth more than the current price.
That does not make insiders infallible.
They can be wrong.
They can buy too early.
They can underestimate risks.
But insider buying can reinforce an investment thesis when the fundamentals already look favorable.
That is how I view Happe's purchase.
It does not create the thesis.
It supports it.
A director buying shares after a period of stock weakness, while margins are improving and earnings are growing, is something I would rather see than the opposite.
It suggests at least one informed person close to the company views the valuation as attractive.
I pay attention to that.
Why the Valuation Looks Interesting
At roughly 9.7 times forward earnings, H.B. Fuller is not priced like a company with an obvious growth story.
The market appears skeptical.
That skepticism is understandable.
The company has debt.
Volumes remain soft.
Integration risk exists.
Industrial markets can be cyclical.
But valuation is ultimately about expectations.
A stock trading at 30 times earnings needs a lot to go right.
A stock trading below 10 times earnings needs far less.
That is what I like about this setup.
I am not paying for perfection.
I am not paying for explosive growth.
I am not paying for a speculative future that may never arrive.
I am looking at a company generating real earnings, expanding margins, producing meaningful cash flow, and slowly improving its balance sheet.
If the company simply continues executing reasonably well, the current valuation begins looking attractive.
If volumes recover and margins remain strong, the upside could be much greater.
Of course, low valuations can stay low for a long time.
That is one reason value investing requires patience.
The market does not owe me a re-rating simply because I think a stock is cheap.
A catalyst helps.
For H.B. Fuller, I see three.
Crossing the 20% adjusted EBITDA margin threshold.
Successfully integrating AMS.
Continuing to reduce leverage.
Those are tangible.
They are measurable.
And they can change investor perception.
What Would Make Me Wrong
Whenever I become interested in a stock, I force myself to think about what would invalidate the thesis.
For H.B. Fuller, several things could.
The first would be deteriorating margins.
If the current margin gains prove temporary and profitability slips back toward historical levels, the valuation may deserve to stay low.
The second would be continued volume weakness.
Pricing can compensate for weak unit demand for a while, but not forever.
If customers begin resisting price increases while volumes remain soft, revenue growth could stall.
The third risk is debt.
If cash flow disappoints or acquisitions create additional balance-sheet pressure, deleveraging could take longer than expected.
That would keep the valuation depressed.
The fourth risk is integration.
If AMS produces fewer synergies than expected or creates operational disruption, management credibility could suffer.
And finally, broader economic weakness could hurt industrial demand.
H.B. Fuller serves industries that ultimately depend on manufacturing activity, construction, consumer spending, packaging demand, electronics production, transportation, and other economic variables.
A severe slowdown would not leave the company untouched.
These risks are real.
That is why I would never call this a risk-free bargain.
There is no such thing.
Why I Still Like the Setup
Even after accounting for those concerns, I keep coming back to the same contradiction.
The stock is down.
The valuation has contracted.
Margins are hitting records.
Earnings are growing.
Cash flow is healthy.
Leverage is slowly improving.
An insider is buying.
That is the combination I want to find before the market fully notices it.
There is a big difference between buying a stock because everything looks perfect and buying a stock because the market is still skeptical while the numbers are improving.
I prefer the second.
When everyone agrees that a company is wonderful, the valuation usually already reflects that enthusiasm.
The better opportunities often appear when the business is improving faster than investor expectations.
That is what I think may be happening here.
H.B. Fuller does not need spectacular growth for the stock to work.
The company simply needs to keep proving that its margins are structurally better than the market believes, continue converting earnings into cash, and use that cash to strengthen the balance sheet.
If management can do that, I think the valuation can rise without requiring heroic assumptions.
My View on H.B. Fuller
At around $50, I view H.B. Fuller as one of the more interesting conventional value opportunities I have encountered recently.
It is not a turnaround in the traditional sense because the business is already producing solid results.
It is not a high-growth company.
It is not a speculative technology story.
It is something simpler.
A profitable industrial company is improving margins while its valuation moves in the opposite direction.
Those situations interest me because they create asymmetric possibilities.
The downside is not nonexistent, especially with the debt load.
But the current valuation already reflects a meaningful amount of skepticism.
If earnings continue growing and leverage improves, the market may eventually decide that a sub-10-times forward earnings multiple is too pessimistic.
I would classify the shares as a Buy, but not an aggressive one.
I would want to build a position gradually rather than chase the stock.
The balance sheet keeps me from treating H.B. Fuller like an obvious bargain.
But the operating momentum keeps me from ignoring it.
My thesis is straightforward.
I am not betting on dramatic revenue acceleration.
I am betting that improved margins are real, cash generation remains strong, leverage continues falling, and investors eventually assign a better multiple to those earnings.
That is a far more conservative thesis than hoping for explosive growth.
And sometimes conservative theses are exactly where the best returns begin.
What I Will Be Watching Next
The first thing I will watch is EBITDA margin.
I want to see whether H.B. Fuller can move above 20% and stay there.
The second is organic volume.
Pricing has done a lot of work.
I want to see units begin contributing.
The third is cash flow.
Management's $300 million to $325 million operating cash flow target matters because debt reduction depends on that cash materializing.
The fourth is net leverage.
I want the trend to continue downward.
If leverage falls materially below 3.0 times, I think the stock becomes easier for more investors to own.
The fifth is AMS.
I want evidence that integration benefits are flowing through the income statement and balance sheet rather than remaining presentation-slide promises.
If all five pieces begin working together, I think the story becomes considerably stronger.
Final Thoughts
H.B. Fuller is exactly the kind of stock I enjoy researching because the investment case is not immediately obvious.
Nothing about the company screams excitement.
The business is industrial.
The products are technical.
The balance sheet is not perfect.
Growth is steady rather than spectacular.
And the stock has not rewarded shareholders recently.
That combination is precisely what creates the opportunity.
Markets are often slow to reconsider companies that have spent time disappointing investors.
Once a narrative forms, it tends to linger.
A company becomes labeled "slow growth."
Then "leveraged."
Then "cyclical."
Then "boring."
Those labels can remain attached long after the numbers begin changing.
I think that may be happening with H.B. Fuller.
The market still appears to be pricing the company based on its risks while not giving enough credit to its operating improvements.
Margins are at record levels.
Earnings are rising faster than revenue.
Cash generation remains meaningful.
Debt is moving in the right direction.
And at least one director appears willing to put personal capital behind the story.
That does not mean the stock is guaranteed to rise.
Nothing in investing works that way.
But when I find a company trading below 10 times forward earnings while profitability is improving, I pay attention.
When that company is also reducing leverage, I become more interested.
And when an insider begins buying shares near the same price I am evaluating, I take another look.
For me, H.B. Fuller is not exciting because it sells adhesives.
It is exciting because the market may be underestimating how much better the economics of the business are becoming.
Sometimes the best investment stories are not built around revolutionary products.
Sometimes they are built around a company quietly becoming more profitable while everyone else is looking somewhere else.
H.B. Fuller may be one of those stories.
Comments
Post a Comment